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In its brief lifetime as a known peptide, somatostatin has provided a truly remarkable story filled
with surprising developments from unexpected quarters. The foundation was set in 1969, when Krulich
and McCann 1 reported that fractions of a crude hypothalamic extract inhibited the secretion of growth
hormone . In 1973, Guillemin's laboratory reported
the sequence and synthesis of a fourteen amino acid
peptide with the same inhibitory effect. 2·3 It occurs in
both a cyclic and linear form, each displaying equal
biological activity. Somatostatin was assigned as its
name, but it is also commonly referred to as growth
hormone release inhibitory factor (G H RI F) or somatotropin-release inhibiting factor (SRIF).
Characterization of somatostatin's biological activity proceeded rapidly once the synthetic peptide
became available. It proved to be a potent inhibitor
of thyroid stimulating hormone (TSH). 4 No effect
was found upon prolactin or adrenocorticotropic
hormone (ACTH) secretion except in the pathological situations of acromegaly 5 and Nelson's syndrome,6 where inhibition has been described. The
secretion of follicle-stimulating hormone (FSH) and
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luteinizing hormone (LH) is not inhibited by somatostatin.7 There was great surprise when investigators
in Seattle, working with baboons, found that somatostatin inhibited the secretion of two pancreatic hormones, insulin and glucagon, 8 and, as studies expanded to other organs, the inhibition of gastrin, 9
secret in , 10 gastric acid and pepsin secretion, 9 and secretin-stimulated exocrine pancreatic secretion 10 were
described. Very little is known about the molecular
mechanisms of somatostatin effects, but clues are
being provided by the findings that inhibition of insulin secretion can be partially reversed by high calcium concentration 11 and by alpha adrenergic blockade with phentolamine. 12 Furthermore, somatostatin
appears to interfere with calcium uptake by islets 13
and may inhibit tissue cyclic adenosine monophosphate (AMP) accumulation. 14 Both events are
thought to be important in the secretory process.
Diabetes researchers became interested when it
was shown that somatostatin infusions caused a fall
of blood glucose in both normal subjects and diabetics .15 In addition, somatostatin markedly slowed the
development of ketoacidosis in insulin-deprived juvenile-type diabetics, 16 even though it did little to reverse established ketoacidosis. 17 Until then there was
no convincing evidence that glucagon was anything
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more than a vestigial hormone, only continual debates about the theoretical relative contributions of
insulin and glucagon to metabolic processes.
The widespread effects of insulin upon hepatic
and peripheral tissues are well known, but glucagon's
effects appear to be more limited. Although pharmacological amounts of glucagon can influence many
organs, physiological concentrations act primarily on
the liver, and probably have minor lipolytic effects on
adipose tissue. Hepatic glycogenolysis and gluconeogenesis can both be stimulated by glucagon, thus
leading to enhanced hepatic glucose output. It is also
now clear that glucagon has a direct stimulatory effect upon hepatic ketogenesis. 18 The issue, however, is
whether these effects are trivial and easily nullified by
small amounts of insulin or whether they are physiologically important. Somatostatin has become a
useful pharmacological tool to help answer these
questions, because in addition to being able to block
insulin and glucagon secretion, it has no known direct effect upon hepatic glucose output or peripheral
glucose utilization. Several laboratories have now
shown that the fall of blood glucose during a somatostatin infusion is secondary to a reduction of hepatic glucose output. The interpretation has therefore
been made that inhibition of glucagon in these shortterm experiments was more important than the inhibition of insulin. A similar fall in glucose was found
in a diabetic with hypophysectomy, indicating that
growth hormone inhibition did not have much influence.15
These unexpected findings made it difficult to
understand why patients with pancreatectomies were
hyperglycemic. According to the results of the somatostatin experiments, the removal of both insulin and
glucagon surgically should have led to hypoglycemia.
One finding used to reconcile this puzzle was that
insulin-deprived pancreatectomized dogs have abundant amounts of extra-pancreatic glucagon which is
known to be primarily of gastric origin. 19 Humans,
however, appear to have very little gastric glucagon. 20
The best explanation for the paradox appears to be
that glucagon's effects are only transient; thus, a
glucagon infusion leads to an increase of hepatic
glucose output which lasts for about an hour. 21 Similarly, if glucagon is "removed" with somatostatin,
there is a transient reduction in hepatic glucose output.22 Therefore, during chronic somatostatin infusions, a fall of blood glucose is seen before hyperglycemia, which appears as insulin deficiency
dominates.22 These experiments and others have led
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some to say that glucagon's influence on blood glucose homeostasis is minor and that the hyperglycemia
of diabetes is almost entirely secondary to insulin
deficiency. The acceptance of a dominant role for
insulin seems inescapable, but glucagon may still
have important effects. Daily physiological events
bear little relation to infusions of glucagon or somatostatin; glucagon concentrations do not remain constant during the day but fluctuate considerably, particularly with meals. Thus, if each one of these
fluctuations led to a transient effect on blood glucose
lasting for even 45 mintues, it is clear that glucagon 's
overall influence throughout the day could be substantial. Furthermore, there is abundant evidence
that glucagon secretion is increased in diabetes.23 To
answer some of these critical question s, workers have
given glucagon infusions and injections, trying to stay
within the concentrations thought to be physiologicaJ.2•- 25 There is agreement that glucagon has
hyperglycemic effects when unopposed by insulin but
disagreement that it causes deterioration of control
during insulin therapy in diabetics. In addition, there .
is growing acceptance that endogenous insulin secretion in normal subjects can effectively counter the
effects of artificially-raised plasma glucagon concentrations. Therefore, despite large amounts of recent
work, there remains much disagreement about glucagon's importance in diabetes.
This rather elaborate background is necessary to
understand somatostatin's possible usefulness as a
therapeutic agent. Its ability to lower blood glucose is
presumed to be mediated primarily via glucagon inhibition. Therefore the question of glucagon's contribution to the hyperglycemia of diabetes is of utmost
importance. During debates about somatostatin's potential in diabetes a commonly raised question is,
"Why worry about somatostatin? Why not give more
insulin?" Somatostatin 's advocates argue that following each meal there is a glucagon rise which drives
blood glucose to unacceptable postprandial peaks
even in so-called well-controlled diabetics. Aborting
these glucagon rises with somatostatin would therefore minimize glucose excursions in a way unachievable with conventional insulin therapy. New data
adding more confusion to these concepts is the finding that somatostatin can impair carbohydrate absorption by the gastrointestinal tract and may lower
postprandial glucose by a mechanism independent of
glucagon. 27
As indicated above, much of the controversy
about somatostatin centers on its possible effects

WEIR AND WEIR: SOMATOSTATIN

upon glucose control irt di a betes. Even though data
showing a connection between blood glucose and
complications is not conclusive, there is enough circumstantial evidence to warrant the pursuit of optimal control. Another factor linked to complications
is growth hormone. Even though large, well-controlled studies are still not available, the weight of
evidence suggests that pituitary ablation has a beneficial effect upon diabetic retinopathy. Possibly important as well is the observation that plasma growth
hormone levels are increased in diabetics , when control is poor 28 or during exercise. 29 ·30 Somatostatin
therefore may possibly benefit diabetics through two
mechanisms-control of blood glucose and suppression of growth hormone secretion.
Obviously much more work is needed before
somatostatin's ultimate value as a therapeutic tool
can be assessed and there are many hurdles which
need to be overcome. Long-acting preparations must
be developed , as injections before each meal are obviously impractical. A protamine-zinc somatostatin
preparation has been found to increase the duration
of action in rats 31 but has been unsuccessful in primates. There were early fears that inhibitory effects
upon platelet function would lead to serious bleeding
problems, but recent thorough studies have dispelled
some of these anxieties. 32 Even though chronic suppression of growth hormone might help some diabetics, growth retardation in children would not be acceptable. Furthermore, it is possible that
somatostatin's effecis on the gastrointestinal tract
will produce discomfort and maldigestion leading to
nutritional deficiency. Efforts are underway to develop so matostatin analogues which will selectively
suppress glucagon secretion and, although selectivity
has not yet been accomplished, a D-tryptophan 8somatostatin analogue has been synthesized which is
eight times more potent than somatostatin in inhibiting growth hormone, insulin, and glucagon secretion.33 In addition to its potential usefulness in diabetes, somatostatin may be of some benefit in the
treatment of acromegaly, 5 peptic ulcer disease, and
metastatic insulinomas and glucogonomas.
Another area of research has focused upon the
localization of somatostatin. lmmunohistochemical
techniques, in particular immunofluorescence, have
been very useful for accurate localization, and radioimmunoassay has permitted quantitation of somatostatin immunoreactivity. The major obstacle in the
development of radioimmunoassays was the problem
of labeling somatostatin. Labeling with 1251 of the
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tyrosine of the synthetic analogue 1-tyrosinated somatostatin provided the breakthrough and several very
specific, highly sensitive assay systems have become
available through the research of Arimura et al 34 and
by Y.C. Patel, MD and S. Reichlin, MD (unpublished data , 1975).
These techniques led to an unexpected and important discovery in late 1974 when Dubois in
France, using immunofluorescence, found somatostatin immunoreactivity in discrete cells of the islets
of Langerhans in several species. 35 This finding was
rapidly confirmed in isolated islets with a specific
radioimmunoassay. 36 Somatostatin was also found
scattered throughout the gastrointestinal tract with
unusually large amounts in the gastric antrum, 37 and
in addition was found in numerous extrahypothalamic areas of the central nervous system, 36 ·38 with
especially large concentrations in the septum and preoptic area, the thalamus, and the cortex. The highest
concentration of somatostatin in the hypothalamus
has been localized to the median eminence and the
arcuate nucleus. 38 Definitive proof that extrahypothal a mic material with somatostatin immunoreactivity is identical to hypothalamic somatostatin
awaits amino acid sequence determination . The material does appear to have biological activity, however, as extracts of frog pancreas with a high content
of somatostatin immunoreactivity have been found
to inhibit growth hormone secretion. 39
I mmunofluorescent techniques were also used to
show that the cells containing somatostatin immunoreactivity in islets and gut were of the D-type. 40 D
cells comprise about 5% to 10% of the mammalian
islet cell population and tend to occur in close proximity to glucagon-containing A cells. In the mouse
and rat, for instance, A and D cells form a rim of
tissue around a central core of B cells. 41 In the horse,
however, there is a central mass of A and D cells with
peripheral cells being B cells, and in man A and D
cells occur together next to capillary walls. The physiological importance of this distribution is as yet unknown, but it seems likely that there is some unique
interaction between A a nd D cells.
An exception to the above pattern is found in
birds which have a population of islets, called light
islets, with D cells and B cells, but almost no A cells. 42
There are also, however, dark islets containing both
A and D cells and few B cells. Birds are also unique
because their pancreases contain high concentrations
of glucagon and somatostatin compared to mam-
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mals, 43·44 but the significance of this can only be speculated upon.
It was assumed by many that normal islet D cells
contained gastrin, largely because the cells of gastrincontaining tumors of the Zollinger-Ellison syndrome
have D-cell-like morphology. Some workers have
found gastrin immunoreactivity in islet tissue, 45 but a
recent thorough study has been unable to confirm
this .46 Thus, the origin of the gastrin-containing cells
of the Zollinger-Ellison syndrome remains undiscovered.
There has been discussion about whether somatostatin in extrahypothalamic cells is synthesized in
situ or taken up following secretion by the hypothalamus. The latter possibility seemed less likely because
of somatostatin's instability in blood and the finding
that the concentration of somatostatin in islets is
comparable to that found in the hypothalamus. Recent studies in the angler fish indicate that somatostatin is synthesized in islets. The angler fish is unique as
it has enormous (100 to 200 mg) islets which can
easily be dissected free and contain no pancreatic
exocrine tissue. lmmunohistochemical studies have
shown that approximately 30% of the cells contain
somatostatin, 20% contain glucagon , and 35% contain insulin. Islets were incubated with the labeled
amino acids 3H-tryptophan and 35 S-cystine, and islet
proteins were separated with column chromatography (P-10) and polyacrylamide gel electrophoresis
(pH 9.5). Clea r pea ks of radioactivity were found in
fractions containing the largest quantity of somatostatin immunoreactivity. 47 Synthetic cyclic somatostatin migrated into the same fractions . Thus there
is now good evidence that somatostatin is synthesized
in situ in islet tissue and there is a lso preliminary
evidence that there is a larger precursor form of
somatostatin (prosomatostatin ). Precursor forms
have been described for a number of other peptides
including insulin and glucagon.
There is currently great interest in defining the
characteristics of the secretory control of somatostatin as this should help solve some of the puzzles about
its physiological role. Data is fragmentary , but studies by G. Patton and co-workers 48 and E . Samo ls
and co-workers 49 ·50 in the isolated perfused canine
and rat pancreas now show that somatostatin secretion can be stimulated by glucagon and arginine.
The present interpretation is th at glucagon probably
has a direct influence upon the D cell, and that the
arginine effect may be indirect, acting via local secretion of glucagon by the A cell.
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Somatostatin' s contribution to the pathophysiology of diabetes has yet to be elucidated, but some
provocative information is available. Following the
induction of diabetes in rats with the B-cell toxin ,
streptozotocin, a significant increase of islet somatostatin content was found using radioimmunoassay
techniques. 51 This author has observed (unpublished
data, 1976) that increased somatostatin in extracts of
whole rat pancreas has been found with streptozotocin, as well as with a lloxan, a different B-cell toxin.
With immunofluorescent techniques it has been possible to show both hypertrophy and hyperplasia of
islet D cells not only in streptozotocin diabetic rats
but also in tissue from two juvenile-type human diabetics.52 These findings may be a secondary phenomenon related to the hypersecretion of glucagon, or
perhaps the hyposecretion of insulin known to occur
in diabetes, or to some other factor. The critical
question is whether there is increased islet somatostatin secretion leading to reduced insulin secretion .
Also, even though diabetics secrete excessive
amounts of glucagon which contribute to hyperglycemia, they might secrete even more glucagon were it
not for D-cell secretion of somatostatin . Therefore,
the D-cell hypertrophy could have either a beneficial
or detrimental influence upon diabetes .
An understanding of somatostatin's physiologic
importance may help us make sense of what is occurring in disease states. There is good reason to think
that somatostatin's effects are exerted locally. It
seems no accident that cells containing somatostatin
are located in close proximity to cells capable of
responding to somatostatin. Because of this proximity and because of somatostatin's instability in blood,
it would seem inefficient for this peptide to be transported through the circulation to distant organs. Unfortunately, it has not yet been possible to measure
physiological levels of somatostatin in plasma. Local
secretory mechanisms are probably important in
many organs, but islets are particularly intriguing.
There is now good evidence that local secretion by
autonomic nerve terminals of norepinephrine and
acetylcholine can influence both glucagon and insulin
secretion. 53 Some data suggest that local insulin secretion suppresses glucagon release from A cells 54 and
there is now reason to suspect that glucagon may
stimulate insulin release, 55 that somatostatin may inhibit the secretion of insulin and glucagon , and that
glucagon may stimulate somatostatin secretion. The
potential interactions which take place in islet interstitial spaces may be extraordinarily complex and
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difficult to clarify. Another possible way in which
different islet cells could communicate is through gap
junctions. Small molecules have been shown to move
from the cytoplasm of one cell into the cytoplasm of
another through these structures. Gap junctions have
been described as otcurring between B cells, and also
between A and B cells, 56 but thorough studies of
possible D-cell gap junctions are not yet available.
Suggestions have also been made that there may be
important electrical interactions between islet cells.
Even though one can make many speculations
about the possible importance of somatostatin in islets and the gastrointestinal tract, no definitive effects
have been elucidated. There is, however, evidence
that somatostatin exerts a physiological influence on
the pituitary. Injections of somatostatin antiserum
into rats led to increases in growth hormone and TSH
secretion, presumably by neutralizing somatostatin in
the hypothalamic-hypophyseal portal circulation. 57 •58
The finding that somatostatin is distributed throughout extrahypothalamic areas of the central nervous
system raises important questions about somatostatin's possible role as a neurotransmitter. There is also
much curiosity about the evolution and embryology
of somatostatin, particularly since its presence is
found in such diverse areas as the central nervous
system, pancreatic islets, and gut. It is worth noting
that another peptide, substance P, has recently been
found in various parts of the brain including the
hypothalamus, and the gut. 7
It was predictable that a "somatostatinoma"
would eventually be found, and 0. P. Ganda and
associates 59 indicate that it has been. A 46-year-old
woman with an eight-year history of well-documented diabetes mellitus was found to have a pancreatic islet cell tumor during a cholecystectomy .
Clinically there was no evidence of its being an insulinoma, glucagonoma, or a tumor of either the
Zollinger-Ellison or pancreati~ cholera (Verner-Morrison) type . Ultrastructurally the majority of the cells
appeared to be of the D-type. The somatostatin content of the tumor was remarkably high (301 ng/ mg of
tissue), and the content of insulin, glucagon, gastrin,
and vasoactive intestinal peptide was negligible.
Pathologically the tumor was judged to be a lowgrade malignancy, and metastatic tissue was found in
one of the 38 resected lymph nodes. Remarkably,
following surgical removal of the entire tumor, glucose values returned to normal and have remained so
for 16 months (a recent fasting blood sugar was 73
mg/ I OOml and two-hour postprandial was 70

mg/ IOOml ). We hypothesized that the patient was
diabetic because of the continued secretion of large
amounts of somatostatin by her tumor . As mentioned above, experimental infusions of somatostatin
in normal subjects produce a fall of blood glucose;
this drop, however, is only transitory, lasting for a
few hours; with a longer infusion, hyperglycemia develops. Studies of insulin, glucagon, and growth hormone secretion in response to an arginine infusion
were done prior to surgery and the response of each
hormone appeared to be diminished, as one might
expect with chronic somatostatin exposure. Unfortunately, it was not possible to repeat the study following surgery . When a patient is found to have an
apparently non-functioning pancreatic tumor of the
islet cell type, especially if diabetes is also present, the
possibility of a somatostatinoma shot.lid be considered.
Somatostatin has proved to be infinitely more
interesting than anyone might have imagined at the
time of its discovery in 1973. Current interest in this
unique peptide is focused upon its potential role in
the pathophysiology and therapy of diabetes mellitus.
It is probable that somatostatin also will come to
occupy an increasingly prominent place in such diverse disciplines as cell biology, the neurosciences,
endocrinology, and gastroenterology.
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